Tissue accumulation of lanthanum as compared to aluminum in rats with chronic renal failure - Possible harmful effects after long-term exposure

Nephron - Experimental Nephrology

Volumn 115, Issue 4, 2010, Pages

  Nikolov, Igor G ^a   Joki, Nobuhiko ^a   Vicca, Stéphanie ^a,b   Patey, Natacha ^a   Auchère, Daniel ^b   Benchitrit, Joyce ^a   Flinois, Jean Pierre ^c   Ziol, Marianne ^d   Beaune, Philippe ^c   Drüeke, Tilman B ^a,c   Lacour, Bernard ^a,b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSERM   (France)

^d HÔPITAL JEAN VERDIER   (France)

Author keywords

Aluminum; Chronic renal failure; Lanthanum; Phosphate binders

Indexed keywords

ALANINE AMINOTRANSFERASE; ALUMINUM HYDROXIDE; ASPARTATE AMINOTRANSFERASE; CYTOCHROME P450; LANTHANUM CARBONATE; PHOSPHORUS; POLYSILANE DELALANDE; UNCLASSIFIED DRUG; ALUMINUM; LANTHANUM;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALUMINUM OVERLOAD; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOACCUMULATION; BODY WEIGHT; CELL PROLIFERATION; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFECT; DRUG EXCRETION; DRUG INTOXICATION; LIVER WEIGHT; LONG TERM EXPOSURE; MALE; NONHUMAN; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RAT; URINARY EXCRETION; ANIMAL; DRUG EFFECTS; HYPERPHOSPHATEMIA; LIVER; METABOLISM; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

ALUMINUM; ALUMINUM HYDROXIDE; ANIMALS; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; LANTHANUM; LIVER; MALE; ORGAN SIZE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 77951242563     PISSN: 16602129     EISSN: None     Source Type: Journal    
DOI: 10.1159/000313492     Document Type: Article

References (31)

1. Slatopolsky E, Delmez JA: Pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 1994; 23: 229-236.
2. Moe SM, Drueke T, Lameire N, et al: Chronic kidney disease-mineral-bone disorder: a new paradigm. Adv Chronic Kidney Dis 2007; 14: 3-12.
3. Neves KR, Graciolli FG, dos Reis LM, et al: Vascular calcification: Contribution of parathyroid hormone in renal failure. Kidney Int 2007; 71: 1262-1270.
4. Block GA, Klassen PS, Lazarus JM, et al: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218.
5. Clarkson EM, Luck VA, Hynson WV, et al: The effect of aluminium hydroxide on calcium, phosphorus and aluminium balances, the serum parathyroid hormone concentration and the aluminium content of bone in patients with chronic renal failure. Clin Sci 1972; 43: 519-531.
6. Alfrey AC, LeGendre GR, Kaehny WD: The dialysis encephalopathy syndrome: possible aluminum intoxication. N Engl J Med 1976; 294: 184-188.
7. Pierides AM, Edwards WG Jr, Cullum UX Jr, et al: Hemodialysis encephalopathy with osteomalacic fractures and muscle weakness. Kidney Int 1980; 18: 115-124.
8. Chertow GM, Burke SK, Raggi P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252.
9. Block GA, Raggi P, Bellasi A, et al: Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71: 438-441.
10. Block GA, Spiegel DM, Ehrlich J, et al: Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68: 1815-1824.
11. Hutchison AJ: Calcitriol, lanthanum carbonate, and other new phosphate binders in the management of renal osteodystrophy. Perit Dial Int 1999; 19(suppl 2):S408-S412.
12. D'Haese PC, Spasovski GB, Sikole A, et al: A multicenter study on the effects of lanthanum carbonate (fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 2003;85:S73-S78.
13. Lacour B, Lucas A, Auchere D, et al: Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int 2005; 67: 1062-1069.
14. Slatopolsky E, Liapis H, Finch J: Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int 2005; 68: 2809-2813.
15. Behets GJ, Verberckmoes SC, Oste L, et al: Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate. Kidney Int 2005; 67: 1830-1836.
16. Spasovski GB, Sikole A, Gelev S, et al: Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant 2006; 21: 2217-2224.
17. Omura T, Sato R: The carbon monoxidebinding pigment of liver microsomes. II. Solubilization, purification, and properties. J Biol Chem 1964; 239: 2379-2385.
18. Hutchison AJ, Maes B, Vanwalleghem J, et al: Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract 2005; 100:c8-c19.
19. Hutchison AJ, Maes B, Vanwalleghem J, et al: Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. Nephron Clin Pract 2006; 102:c61-c71.
20. Joy MS, Finn WF: Randomized, doubleblind, placebo-controlled, dose-titration, phase iii study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 2003; 42: 96-107.
21. Sprague SM, Abboud H, Qiu P, et al: Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol 2009; 4: 178-185.
22. Bervoets AR, Behets GJ, Schryvers D, et al: Hepatocellular transport and gastrointestinal absorption of lanthanum in chronic renal failure. Kidney Int 2009; 75: 389-398.
23. Bervoets AR, Oste L, Behets GJ, et al: Development and reversibility of impaired mineralization associated with lanthanum carbonate treatment in chronic renal failure rats. Bone 2006; 38: 803-810.
24. Yang Z, Schryvers D, Roels F, et al: Demonstration of lanthanum in liver cells by energy- dispersive X-ray spectroscopy, electron energy loss spectroscopy and high-resolution transmission electron microscopy. J Microsc 2006; 223: 133-139.
25. Ben-Dov IZ, Pappo O, Sklair-Levy M, et al: Lanthanum carbonate decreases pth gene expression with no hepatotoxicity in uraemic rats. Nephrol Dial Transplant 2007; 22: 362-368.
26. Ittel TH, Steinhausen C, Kislinger G, et al: Ultrasensitive analysis of the intestinal absorption and compartmentalization of aluminium in uraemic rats: a 26Al tracer study employing accelerator mass spectrometry. Nephrol Dial Transplant 1997; 12: 1369-1375.
27. Drueke T, Lacour B, Touam M, et al: Oral aluminum administration to uremic, hyperparathyroid, or vitamin D-supplemented rats. Nephron 1985; 39: 10-17.
28. Nolin TD, Appiah K, Kendrick SA, et al: Hemodialysis acutely improves hepatic cyp3a4 metabolic activity. J Am Soc Nephrol 2006; 17: 2363-2367.
29. Michaud J, Naud J, Chouinard J, et al: Role of parathyroid hormone in the downregulation of liver cytochrome p450 in chronic renal failure. J Am Soc Nephrol 2006; 17: 3041-3048.
30. Hutchison AJ, Barnett ME, Krause R, et al: Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Nephron Clin Pract 2008; 110:c15-c23.
31. Behets GJ, Dams G, Vercauteren SR, et al: Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure? J Am Soc Nephrol 2004; 15: 2219-2228.